Women Powered Science.
A steadfast champion of women with cancer.
Dr. van ‘t Veer is the co-founder and Chief Research Officer at Agendia and the proud inventor of MammaPrint.
Additionally, she is the Professor of Laboratory Medicine and Director of Applied Genomics at the University of California San Francisco and head of the NKI’s DNA-Diagnostic Laboratory.
A steadfast champion of women with cancer.
Dr. van ‘t Veer is the co-founder and Chief Research Officer at Agendia and the proud inventor of MammaPrint.
Additionally, she is the Professor of Laboratory Medicine and Director of Applied Genomics at the University of California San Francisco and head of the NKI’s DNA-Diagnostic Laboratory.
A steadfast champion of women with cancer.
Dr. van ‘t Veer is the co-founder and Chief Research Officer at Agendia and the proud inventor of MammaPrint.
Additionally, she is the Professor of Laboratory Medicine and Director of Applied Genomics at the University of California San Francisco and head of the NKI’s DNA-Diagnostic Laboratory.
Dr. van ‘t Veer is a superwoman in the world of personalized medicine.
For over three decades, she has been advancing breast cancer care through world-shaking innovations, earning her over 230 publications and awards. Renown journal, 24/7 Wall Street named her one of the 32 Amazing Women Inventors who have succeeded in fields dominated by men.
Inspired from a young age, her work is based on the belief that there’s no one-size-fits-all treatment for breast cancer patients. She has made it her mission to increase every woman’s chance of surviving this disease by helping doctors take a more individualized approach to medicine.
Dr. van ‘t Veer is best known for a discovery that she and her team made at the Netherlands Cancer Institute (NKI). They established that a specific DNA signature made up of 70 genes could determine whether breast cancer tumors had a low or high risk of recurrence. This was the foundation for her revolutionary test, MammaPrint. After patenting the innovation, Dr. van ‘t Veer and her research partner, René Bernards, started Agendia as a way to bring MammaPrint and other life-changing genomic technology to breast cancer patients around the world.
“During high school, I remember learning about genes — how they were the beginning of life and the drivers of how our body functions. That rich experience made me sure I wanted to pursue a career in medical research.” – Dr. van ‘t Veer
Awards and accolades based on the impact of MammaPrint.
Named one of “America’s Fastest-Growing Private Companies” on 2020 INC 5000
The American Society of Breast Surgeon Foundation Award
The American Medical Association Award
Susan G. Komen The Brinker Award for Scientific Distinction
AACR Outstanding Investigator Award for Breast Cancer Research
Co-founder, Laura van ‘t Veer, inducted into the 2020 class of “Giants of Cancer Care” in Cancer Diagnostics
Co-founder Laura van ‘t Veer, given the European Union Women Innovator Award
Co-founder, René Bernards, elected as an international member of the National Academy of Sciences (NAS)
